Protocol Ledger

NCT03742973 · Phase II · TERMINATED

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Interventional Phase II clinical trial protocol NCT03742973 sponsored by Eli Lilly and Company in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-28 Enrollment: 2 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03742973
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03742973
Protocol FieldVerified Registry Value
NCT IdentifierNCT03742973
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment2 participants (ACTUAL)
Registered Start Date2019-03-28
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI